Andere talen Organovo Holdings, Inc.

Aandelen

ONVO

US68620A2033

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 01-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,9311 ^USD	-12,98%		-6,89%	-16,12%

15/04	Organovo's medicijn tegen leververvetting bereikt hoofddoel in tussentijds onderzoek	RE
15/04	Organovo Holdings, Inc. Kondigt positieve Fase 2-resultaten aan voor FXR314 in metabole dysfunctie-geassocieerde steatohepatitis, met zowel vermindering van het levervetgehalte als sterke veiligheid en verdraagbaarheid in vergelijking met placebo	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	16/04
Organovo's fatty liver disease drug meets main goal in mid-stage study	15/04
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	15/04
Organovo Holdings, Inc. Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo	15/04
Organovo: Fiscal Q3 Earnings Snapshot	08/02
Organovo Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	08/02
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress	25/01
Organovo Holdings, Inc. Presents FXR314 3D Human Tissue Model Findings	25/01
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress	09/01
Organovo Provides Timing for Release of FXR314 Phase 2 NASH Results	06/12
Organovo Holdings, Inc. Provides Timing for Release of FXR314 Phase 2 NASH Results	06/12
Organovo: Fiscal Q2 Earnings Snapshot	10/11
Organovo Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	09/11
Organovo Highlights FXR314 Combination Therapy Potential and Plan	08/11
Organovo Holdings, Inc. Highlights FXR314 Combination Therapy Potential and Plan	08/11
Organovo : Submission of Matters to a Vote of Security Holders - Form 8-K	03/11
Organovo to Participate in the H.C. Wainwright Global Investment Conference	08-09-23
Organovo : Change in Certifying Accountants - Form 8-K	05-09-23
Organovo Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data	23-08-23
Organovo Holdings, Inc. Advances Clinical Timelines for FXR314 and Provides Updates on NASH Phase 2 Data	23-08-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Organovo Holdings, Inc.

Aandelen

ONVO

US68620A2033

Andere talen

Filters